TransGenic Inc. entered into a joint research agreement with Immuno-Biological Laboratories Co. Ltd. The agreement concludes with the immunological biology laboratory to investigate the toxic Ã42 (AÃ42) was used as an AD therapeutic agent by using TransGenic's model mouse. TransGenic will evaluate effectiveness and efficacy and jointly study the feasibility of development as a pharmaceutical product and as a drug manufacturer as early as possible.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
460 JPY | -0.43% | -2.13% | -6.69% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-6.69% | 27.85M | |
+26.63% | 681B | |
+21.85% | 556B | |
-5.16% | 361B | |
+17.15% | 325B | |
+5.08% | 285B | |
+13.68% | 235B | |
+3.65% | 199B | |
-11.12% | 189B | |
-4.38% | 157B |
- Stock Market
- Equities
- 4570 Stock
- News Immuno-Biological Laboratories Co., Ltd.
- Transgenic Inc. Enters into Joint Research Agreement with Immuno-Biological Laboratories Co. Ltd